Third Amendment to Exclusive Distribution Agreement dated December 22, 2022, by and between Revance Therapeutics, Inc. and Teoxane SA

A.On January 10, 2020, the Parties entered into an Exclusive Distribution Agreement (the Original Exclusive Distribution Agreement) to distribute certain products in the Territory.

B.On September 1, 2020, the Parties entered into a First Amendment to the Exclusive Distribution Agreement to postpone the Launch Date (the First Amendment Agreement).

C.On November 18, 2020, the Parties entered into a Second Amendment to the Exclusive Distribution Agreement to update the Innovation Plan and Clinical Trial Costs (the Second Amendment Agreement).

D.The Original Exclusive Distribution Agreement, the First Amendment Agreement, and the Second Amendment together are referred to as the Exclusive Distribution Agreement. Unless otherwise defined herein, capitalized terms used in this preamble and in this third amendment to the exclusive distribution agreement dated January 10, 2020 (this Third Amendment Agreement) shall have the meaning assigned to them in the Exclusive Distribution Agreement.

E.The Parties wish to update Annex 6.3 – Quality Agreement of the Exclusive Distribution Agreement.

F.The purpose of this Third Amendment Agreement is to formally amend the Exclusive Distribution Agreement in accordance with its Clause 19.7 in order to reflect the Parties new agreements regarding the above.

As of the effective date of this Third Amendment Agreement, as set forth in Section 3 below, Annex 6.3 – Quality Agreement of the Exclusive Distribution Agreement shall be replaced by Annex 6.3 – First Restated and Amended Quality Agreement attached to this Third Amendment Agreement.

Other than as set for in this Third Amendment Agreement, the Exclusive Distribution Agreement and its Annexes shall not be amended, changed, modified or varied any way.

The amendments set forth in this Third Amendment Agreement shall become effective upon the date of its execution by both Parties.

This Third Amendment Agreement and the Exclusive Distribution Agreement including its Annexes, taken together, shall constitute one and the same agreement for all purposes to be designated as the Exclusive Distribution Agreement.

Each Party shall bear its own taxes, costs and expenses related to the preparation, execution and performance of this Third Amendment Agreement.

a.This Third Amendment Agreement shall for all purposes be governed by and interpreted in accordance with the laws of [*], without giving effect to conflicts of laws principles. The Parties agree that the United Nations Convention on Contracts for the International Sale of Goods is specifically excluded from application to this Third Amendment Agreement.

b.Any dispute arising from or relating to this Third Amendment Agreement shall be submitted to final and binding arbitration in accordance with Clause 19.10(b) to Clause 19.10(e) of the Exclusive Distribution Agreement.

This Third Amendment Agreement may be executed in one or more counterparts, each of which will be deemed to be an original copy of this Third Amendment Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement, including counterparts transmitted via facsimile or by PDF file (portable document format file).